ES2906614T3 - Agente para evitar o mejorar el deterioro de la función cerebral - Google Patents

Agente para evitar o mejorar el deterioro de la función cerebral Download PDF

Info

Publication number
ES2906614T3
ES2906614T3 ES13850415T ES13850415T ES2906614T3 ES 2906614 T3 ES2906614 T3 ES 2906614T3 ES 13850415 T ES13850415 T ES 13850415T ES 13850415 T ES13850415 T ES 13850415T ES 2906614 T3 ES2906614 T3 ES 2906614T3
Authority
ES
Spain
Prior art keywords
salt
citrulline
citicoline
decreased
brain function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13850415T
Other languages
English (en)
Spanish (es)
Inventor
Kota Kumagai
Masahiko Morita
Takahiro Hara
Kohji Fukunaga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Hakko Bio Co Ltd
Original Assignee
Kyowa Hakko Bio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Bio Co Ltd filed Critical Kyowa Hakko Bio Co Ltd
Application granted granted Critical
Publication of ES2906614T3 publication Critical patent/ES2906614T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES13850415T 2012-10-30 2013-10-30 Agente para evitar o mejorar el deterioro de la función cerebral Active ES2906614T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012238542 2012-10-30
PCT/JP2013/080053 WO2014069667A1 (en) 2012-10-30 2013-10-30 Agent for preventing or improving decline in brain function

Publications (1)

Publication Number Publication Date
ES2906614T3 true ES2906614T3 (es) 2022-04-19

Family

ID=50627559

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13850415T Active ES2906614T3 (es) 2012-10-30 2013-10-30 Agente para evitar o mejorar el deterioro de la función cerebral

Country Status (9)

Country Link
US (2) US10905705B2 (enExample)
EP (1) EP2914270B1 (enExample)
JP (1) JP6166786B2 (enExample)
AU (1) AU2013339058B2 (enExample)
CA (1) CA2889109C (enExample)
ES (1) ES2906614T3 (enExample)
NZ (1) NZ707081A (enExample)
PL (1) PL2914270T3 (enExample)
WO (1) WO2014069667A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2914270B1 (en) 2012-10-30 2022-01-12 Kyowa Hakko Bio Co., Ltd. Agent for preventing or improving decline in brain function
US11583546B2 (en) 2014-04-30 2023-02-21 Kyowa Hakko Bio Co., Ltd. Administration of citicoline to improve cognitive performance, attentional performance, and motor function
CN117069780A (zh) 2016-10-06 2023-11-17 协和发酵生化株式会社 胞苷二磷酸胆碱的晶体及其制造方法
JP7142284B2 (ja) * 2017-06-06 2022-09-27 株式会社らいむ 神経伸長促進剤
JP2019218284A (ja) * 2018-06-18 2019-12-26 オンガネジャパン株式会社 若齢者学習能力向上のための経口組成物及び若齢者の学習能力を向上させる方法
WO2025258678A1 (ja) * 2024-06-13 2025-12-18 キリンホールディングス株式会社 神経回路の興奮を促進するための組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2213000A1 (en) * 1995-03-06 1996-09-12 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US20060046982A1 (en) * 2004-08-26 2006-03-02 Waugh William H Orthomolecular medical use of L-citrulline for capillary endothelial protection and adjacent cell protection in neurodegenerative disease
JP5931325B2 (ja) * 2008-01-30 2016-06-08 協和発酵バイオ株式会社 注意集中力向上剤
CN102316852A (zh) * 2009-02-11 2012-01-11 丽卡实验有限公司 脂质胞二磷胆碱注射液
ES2345802B1 (es) * 2009-03-30 2011-09-08 Hospital Clinic I Provincial De Barcelona Composicion farmaceutica para el tratamiento neuroprotector en pacientes con ictus.
EP2914270B1 (en) 2012-10-30 2022-01-12 Kyowa Hakko Bio Co., Ltd. Agent for preventing or improving decline in brain function

Also Published As

Publication number Publication date
CA2889109C (en) 2020-09-01
AU2013339058B2 (en) 2017-09-07
EP2914270A4 (en) 2016-03-16
WO2014069667A1 (en) 2014-05-08
US20150306125A1 (en) 2015-10-29
AU2013339058A1 (en) 2015-05-07
US20210113601A1 (en) 2021-04-22
US11738037B2 (en) 2023-08-29
EP2914270A1 (en) 2015-09-09
US10905705B2 (en) 2021-02-02
EP2914270B1 (en) 2022-01-12
JP2015535241A (ja) 2015-12-10
PL2914270T3 (pl) 2022-03-14
CA2889109A1 (en) 2014-05-08
NZ707081A (en) 2019-03-29
JP6166786B2 (ja) 2017-07-19

Similar Documents

Publication Publication Date Title
US11738037B2 (en) Agent for preventing or improving decline in brain function
ES2861583T3 (es) Preparación oral de acción rápida que puede aumentar el nivel de arginina en sangre y que comprende citrulina y arginina
ES2458353T3 (es) Preparación que comprende aminoácidos y plantas y su actividad en la destoxificación de alcohol y en el tratamiento de la migraña
ES2955713T3 (es) Agente de mejora de la función visual, y método para mejorar la función visual
JP2023145496A (ja) 神経細胞損傷の治療のためのアミノ酸組成物
EP3130336A1 (en) Food and/or nutraceutical composition containing pea
US10617660B2 (en) Compositions containing benzoate compound and tannic acid for treating central nervous system disorders
JP5085541B2 (ja) 疲労軽減剤
ES2940822T3 (es) Agente elevador de la concentración de óxido nítrico
ES2730736T3 (es) Uso de oligosacáridos no digeribles
ES2736183T3 (es) Composición de absorción oro-bucal para neuro-protector
JP5931325B2 (ja) 注意集中力向上剤
CA3211891A1 (en) Paraxanthine-based compositions for promoting weight loss
US20180207113A1 (en) Vivo intracellular reprogramming composition and method of making and using same
Nersesova et al. Review of the evidence of radioprotective potential of creatine and arginine as dietary supplements
AU2013339057B2 (en) Agent for preventing or improving decline in brain function
WO2024181959A1 (ru) Фармацевтическая композиция для цитостатической и лучевой противоопухолевой терапии
CA3032698C (en) Compositions containing benzoate compound and tannic acid for treating central nervous system disorders